BioCentury
ARTICLE | Clinical News

NEOD001: Phase III started

January 12, 2015 8:00 AM UTC

Prothena began the double-blind, placebo-controlled, international Phase III VITAL trial to evaluate 24 mg/kg IV NEOD001 every 28 days in about 230 newly diagnosed, treatment-naïve patients with cardi...